Figure S4. Gating strategy on CD8+ OT-1 T cells after 24 h and 42 h culture. Figure S5. PMN-MDSCs increase IFN-γ secretion levels upon co-culture with OVA-stimulated OT-1 splenocytes. Figure S6. IFN-γR-/- and IRF-1-/- MDSCs enhance IFN-γ production by activated CD8+ T cells on a per cell basis. Figure S7. MO- and PMN-MDSCs do not augment IL-12 levels upon

co-culture with OVA-stimulated OT-1 splenocytes. Figure S8. MO- and especially PMN-MDSCs suppress T-bet expression in activated CD8+ T cells. Figure S9. MDSCs down-modulate IL-2 production by activated CD8+ T cells. Figure S10. MO-MDSCs down-regulate CD25 expression and STAT5 phosphorylation. Figure S11. MDSCs alter the expression levels of cell adhesion molecules on CD8+ T Daporinad ic50 cells. Figure S12. MO-MDSCs augment Fas expression on activated CD8+ T cells. Selumetinib Figure S13. Neither MO- nor PMN-MDSCs are targets for OVA-specific CTLs, nor do they affect the cytotoxic activity of mature CTLs. Figure S14. Unseparated splenic MDSCs affect CD8+ T-cell activation events. Figure S15. RMA-OVA-induced splenic MDSCs affect CD8+ T-cell activation events. Figure S16. MDSCs differentially affect CD8+ T-cell activation events upon polyclonal

stimulation. Figure S17. Tumor-infiltrating MO-MDSCs are strongly anti-proliferative and recapitulate only some aspects of their splenic counterparts. “
“In clinical Amisulpride practice it is possible to find patients with clinical signs suggestive of anti-phospholipid syndrome (APS) who are persistently negative for the routinely used anti-phospholipid antibodies (aPL). Therefore, the term proposed for these cases was seronegative APS (SN-APS). We investigated the clinical

usefulness of thin-layer chromatography (TLC) immunostaining in detecting serum aPL in patients presenting clinical features of SN-APS. Sera from 36 patients with SN-APS, 19 patients with APS, 18 patients with systemic lupus erythematosus (SLE), 20 anti-hepatitis C virus (HCV)-positive subjects and 32 healthy controls were examined for aPL using TLC immunostaining. Anti-β2-glycoprotein-I, anti-annexin II, anti-annexin V and anti-prothrombin antibodies were tested by enzyme-linked immunosorbent assays (ELISA). Eahy926, a human-derived endothelial cell line, was incubated with immunoglobulin (Ig)G fraction from SN-APS patients and analysis of phospho-interleukin (IL)-1 receptor-associated kinase (IRAK) and phospho-nuclear factor (NF)-κB was performed by Western blot, vascular cell adhesion molecule 1 (VCAM-1) expression by cytofluorimetric analysis and supernatants tissue factor (TF) levels by ELISA. TLC immunostaining showed aPL in 58·3% of SN-APS patients: anti-cardiolipin in 47·2%, anti-lyso(bis)phosphatidic acid in 41·7% and anti-phosphatidylethanolamine in 30·5%. Six of 36 patients showed anti-annexin II.